Lenalidomide: all 818 studies that test it
Page 1 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingNCT07839247Phase 2
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 2
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingNCT07719855Phase 3
- Efficacy and Safety of Lenalidomide in Patients With IgG4-Related DiseaseNot yet recruitingNCT07719543Phase 3
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Phase 4
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingNCT07639138Phase 2
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingRecruitingNCT07485647Phase 2
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07460362Phase 2
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Combining Latency Reversing Agents to Address the HIV ReservoirNot yet recruitingNCT07384624Phase 1/2
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
- Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical StudyRecruitingNCT07240194Phase 2
- Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingNCT07208981Phase 2
- Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman DiseaseRecruitingNCT07187167Phase 2
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseRecruitingNCT07068165Phase 2/3
- Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 2
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus ErythematosusNot yet recruitingNCT06965244Phase 3
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingNCT06918002Phase 3
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseRecruitingNCT06910124Phase 2
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialRecruitingNCT06863584Phase 2
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/2
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingNCT06760156Phase 2
- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaRecruitingNCT06723457Phase 2
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingNCT06461988Phase 2
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Optimizing Reversal of HIV Latency With Combination TherapyNot yet recruitingNCT06240520Phase 1/2
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
- MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive ImpairmentNot yet recruitingNCT06177028Phase 2
- Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
- Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)RecruitingNCT06087653Phase 1/2
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06015880Phase 1
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT06006117Phase 3
- Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RSNot yet recruitingNCT06004765Phase 4
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingNCT05848765Phase 2
- Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCCNot yet recruitingNCT05831969Phase 2
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
- A Clinical Study of Injectable IMM0306 in Combination With LenalidomideNot yet recruitingNCT05771883Phase 1/2
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Phase 4
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
- Lenalidomide in the Treatment of Mucosal Behçet's SyndromeRecruitingNCT05449548Not applicable
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingNCT05351593Phase 1/2
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingNCT05344833Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System LymphomaRecruitingNCT05260619Phase 2
- Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Phase 3
- Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05145400Phase 2
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingNCT04792502Phase 2
- Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaRecruitingNCT04669171Phase 1/2
- Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.RecruitingNCT04627753Phase 2
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT04481815Phase 2
- Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC RearrangementRecruitingNCT04432714Phase 1/2
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2